<DOC>
	<DOCNO>NCT01393561</DOCNO>
	<brief_summary>This multicenter clinical trial , phase III , superiority , control active medicine , double-blind , randomize , enroll 166 child , 12 year old , acute inflammation upper airway , characterize nasal congestion runny nose , last least 24 hour maximum 48 hour prior inclusion . The subject allocate 2 parallel group , receive medicine study , accord randomization .</brief_summary>
	<brief_title>Efficacy Safety Combination Brompheniramine Phenylephrine Symptoms Relief Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Brompheniramine</mesh_term>
	<criteria>1 . Patients 12 year old , sex , remain feasibility legal representant accord need , able understand provide ICF able allow compliance treatment requirement protocol , accord age group ; 2 . Patients symptoms acute inflammation upper airway , start 24 48 hour inclusion study protocol ; 3 . Presence runny nose classification moderate severe ( score 2 3 ) , accord responsible evaluation , 4 . Presence nasal congestion classification moderate severe ( score 2 3 ) , accord responsible evaluation . 1 . Patients 12 year old weight less 40kg ; 2 . History nasal obstruction chronic rhinosinusitis / nasal polyposis ; 3 . Oral chronic respirator history six month ; 4 . Personal history nasal surgery opinion investigator influence resistance nasal airflow ; 5 . Patients clinical history confirm ( diagnose ) asthma ; 6 . Patients medicine treatment chronic allergy ; 7 . Patients gastroesophageal reflux disease ; 8 . Presence psychiatric illness kind ; 9 . Presence mental retardation cause ; 10 . Diagnosis renal hepatic failure ; 11 . Patients genetic syndrome ; 12 . History hypersensitivity ( ) drug ( ) study excipients ; 13 . Use prohibit medicine within prescribed period V0 Inclusion Visit ( Table 1 ) ; 14 . Patients participate last 12 month , clinical trial protocols ; 15 . Patients didn´t updated vaccine book , accord age group ; 16 . Relatives sponsor´s study site´s employee ; 17 . Suggestive sign bacterial infection upper airway rhinoscopy , otoscopy oroscopy ; 18 . Presence anemic/inflamed turbinate anterior rhinoscopy ; 19 . Presence septal deviation grade II III ( region nasal cavity ) / nasal polyp , condition determinant nasal obstruction ; 20 . Presence purulent mucopurulent secretion , nasal vault mal formation ( cleft lip cleave nasolabial correct ) nasal vestibule ; 21 . Current evidence clinically significant disease : hematopoietic , gastrointestinal , cardiovascular , hepatic , renal , neurological , endocrine , psychiatric , autoimmune , pulmonary , another disease block patient participation ; 22 . Any finding clinical observation ( anamnesis physical exam ) laboratory abnormality ( eg , blood glucose , blood count ) , disease ( example , liver , cardiovascular system , lung ) therapy , opinion investigator , may endanger patient interfere endpoint study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Rhinitis</keyword>
	<keyword>Common cold</keyword>
	<keyword>Nasal symptom</keyword>
	<keyword>Children</keyword>
</DOC>